<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza A virus (IAV) infections usually cause acute respiratory disease with substantial morbidity and mortality [
 <xref rid="B1" ref-type="bibr">1</xref>]. According to the World Health Organization (WHO), seasonal influenza causes up to 650,000 deaths annually [
 <xref rid="B2" ref-type="bibr">2</xref>]. Vaccines and antivirals are effective countermeasures in combating IAV infections. However, current influenza vaccines require reformulation annually and do not always match circulating strains, while resistance to marketed anti-influenza drugs are increasingly emerging [
 <xref rid="B3" ref-type="bibr">3</xref>â€“
 <xref rid="B5" ref-type="bibr">5</xref>]. Therefore, novel antivirals with different mechanism of action are urgently needed.
</p>
